AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 APR 5 - (NewsRx.com & NewsRx.net) -- The results of a follow-up analysis of the landmark Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study provide important new evidence regarding the benefits of cholesterol-lowering treatment with pravastatin for women with a prior history of coronary heart disease.
The study, titled "Long-Term Treatment With Pravastatin Reduces Coronary Heart Disease Mortality in Women With Prior Coronary Heart Disease and Average Cholesterol Levels," demonstrates that women with a prior history of coronary heart disease and average cholesterol levels who were placed on pravastatin had a significant 31% reduction in coronary heart disease (CHD) deaths when compared to the women in the study who were initially assigned to placebo. In absolute terms, CHD deaths were reduced from 9.9% in those on placebo to 6.7% for those given pravastatin. The results of the study were presented March 19, 2001, at the 50th Annual Scientific Sessions of the American College of Cardiology (ACC).
The LIPID study was originally designed as a six-year, double-blind, placebo controlled study, consisting of 9,014 male and female patients who had either suffered a heart attack or had a history of unstable angina (severe chest pains). Half of these patients were placed on pravastatin, and half received placebo. At the conclusion of the trial, investigators conducted an additional two-year follow up analysis of patients from the ...
Source: HighBeam Research, Cholesterol-Lowering Drug Reduces Deaths Among Women By 31%.